Latest Conference Articles

In one of his SDPA 2022 presentations, Dr. Rosen spoke on different dermatological conditions with vitiligo-like presentations.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.

During her SDPA 2022 presentation, Cynthia Trickett explored the topic of psoriasis, including comorbidities and treatment options.

New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.

An interview on several major highlights from Dr. Orozsco’s presentation about the greater visibility and importance of physician associates at SDPA 2022.

An interview with Dr. Orozco regarding her presentation at SDPA 2022 on the topic of physician associates and their value in the modern medical system.

An SDPA 2022 interview with Dr. Robert Kirsner regarding his presentation regarding the topic of wound healing and related changes in the field.

An interview at the SDPA 2022 Conference on major talking points from Dr. Robert Kirsner’s presentation on wound care with dermatologists and physician associates.

An interview from SDPA 2022 regarding highlights from Dr. Robert Kirsner’s presentation on dermatologists and wound healing.

Dr. Jula Inrig explains the mechanism of action for the Dual Endothelin Angiotensin Receptor Antagonist (DEARA) investigational candidate Sparsentan, for rare kidney diseases.

The time of flare was significantly shorter in the placebo group compared to the baricitinib.

For safety, the proportions of patients with serious treatment-emergent adverse events in the second treatment period were similar between the treatment groups.

Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

The results show 88.1% of patients with rheumatoid arthritis in the study developed humoral immunogenicity.

A post hoc subgroup analysis compared TNFi-IR patients receiving upadacitinib 15 mg once daily in 3 Phase 3 clinical trials: SELECT-BEOYND, SELECT-CHOICE, and SELECT-COMPARE.

There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.

The results also show substantial medication substitution across prescription drug classes related to medical cannabis use.

The median time-to-remission was longer for women compared to men.

Individuals who were socially isolated at time of fracture had significantly worse function, ability to participate in social roles, and depression time of fracture.

The results show improvements in RAPID3, pain, fatigue, and morning stiffness at weeks 8 and 12 among patients treated with upadacitinib.

Patients with ankylosing spondylitis generally had more favorable outcomes compared to those with psoriasis or psoriatic arthritis.

In data presented during ACR, investigators find peresolimab could be an effective treatment for adult patients with rheumatoid arthritis.

The efficacy of H pylori treatments has waned in recent years, largely because of clarithromycin resistance.

At AHA 2022, Dr. Ray discusses the findings from the phase II open-label extension trial and highlights other important trial data for lipidologists.

The approval of risankizumab represents the first ever IL-23 approved by the FDA for IBD.

A deep dive into exciting late-breaking trial data at AHA 2022, differences in chest pain guidelines, and bringing patient voice into clinical research.

A Q&A with Dr. Bonaca highlights new data on rivaroxaban for PAD and the late-breaking science at AHA 2022.

At the International Pediatric Sleep Association (IPSA) Congress 2022, investigators from Sleep Number presented 2 investigations that utilized its smart bed technology to analyze pediatric sleep behaviors.

The trial achieved its primary efficacy endpoint of terminating PSVT with self-administered etripamil, using symptom-based optional repeat dosing.